A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Guadecitabine (Primary)
- Indications Gastrointestinal stromal tumours; Paraganglioma; Phaeochromocytoma; Renal cell carcinoma
- Focus Therapeutic Use
- 15 Aug 2017 Status changed from not yet recruiting to recruiting.
- 12 Aug 2017 Planned initiation date changed from 16 Aug 2017 to 18 Aug 2017.
- 10 Aug 2017 Planned initiation date changed from 14 Aug 2017 to 15 Aug 2017.